These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32179081)

  • 1. Interleukin 4 and interleukin 13 inhibition: A promising therapeutic approach in bullous pemphigoid.
    Geller S
    J Am Acad Dermatol; 2020 Jul; 83(1):37-38. PubMed ID: 32179081
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
    Russo R; Cozzani E; Gasparini G; Parodi A
    Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
    Takamura S; Teraki Y
    J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
    Saleh M; Reedy M; Torok H; Weaver J
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab cuts both ways.
    Heymann WR
    J Am Acad Dermatol; 2020 Jul; 83(1):35-36. PubMed ID: 32437719
    [No Abstract]   [Full Text] [Related]  

  • 8. Case report: Dupilumab for the treatment of bullous pemphigoid.
    Wang M; Wang J; Shi B
    Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab for bullous pemphigoid with intractable pruritus.
    Seidman JS; Eichenfield DZ; Orme CM
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
    Wang SH; Zuo YG
    Front Immunol; 2021; 12():800609. PubMed ID: 34887875
    [No Abstract]   [Full Text] [Related]  

  • 11. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells.
    Teraki Y; Hotta T; Shiohara T
    J Invest Dermatol; 2001 Nov; 117(5):1097-102. PubMed ID: 11710918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
    Pop SR; Strock D; Smith RJ
    Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
    [No Abstract]   [Full Text] [Related]  

  • 13. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
    Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
    J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab as a novel therapy for bullous pemphigoid.
    Zhang X; Man X; Tang Z; Dai R; Shen Y
    Int J Dermatol; 2023 Apr; 62(4):e263-e266. PubMed ID: 36440691
    [No Abstract]   [Full Text] [Related]  

  • 15. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.
    Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C
    Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201
    [No Abstract]   [Full Text] [Related]  

  • 16. A severe case of IgA bullous pemphigoid successfully treated with dupilumab.
    Valenti M; De Giacomo P; Lavecchia A; Valenti G
    Dermatol Ther; 2022 Nov; 35(11):e15890. PubMed ID: 36181411
    [No Abstract]   [Full Text] [Related]  

  • 17. Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study.
    Simon D; Yousefi S; Cazzaniga S; Bürgler C; Radonjic S; Houriet C; Heidemeyer K; Klötgen HW; Kozlowski E; Borradori L; Simon HU
    Allergy; 2020 Mar; 75(3):669-672. PubMed ID: 31230371
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China.
    Qi W; Rushan X
    Int Immunopharmacol; 2023 May; 118():110050. PubMed ID: 37003187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
    Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
    Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab.
    Li W; Cai S; Man X
    Dermatol Ther; 2022 Feb; 35(2):e15243. PubMed ID: 34854196
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.